Multiple Myeloma

Subscribe to Selected New Research on Multiple Myeloma

8831 relevant articles (651 outcomes, 1256 trials/studies) found for this Disease

Description: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.

Also Known As:

Multiple Myelomas; Myeloma, Multiple; Myeloma, Plasma Cell; Myelomas, Multiple; Myelomas, Plasma-Cell; Plasma-Cell Myeloma; Plasma-Cell Myelomas; Myeloma, Plasma-Cell

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Non-Hodgkin Lymphoma (Lymphosarcoma)
3.	Breast Neoplasms (Breast Cancer)
4.	Neoplasm Metastasis (Metastasis)
5.	Pain (Aches)

Experts

1.	Anderson, Kenneth C: 118 articles (10/2008 - 01/2002)
2.	Hideshima, Teru: 80 articles (07/2008 - 02/2002)
3.	Chauhan, Dharminder: 61 articles (05/2008 - 02/2002)
4.	Barlogie, Bart: 47 articles (08/2008 - 01/2002)
5.	Munshi, Nikhil C: 46 articles (07/2008 - 02/2002)
6.	Richardson, Paul G: 45 articles (09/2008 - 06/2002)
7.	Podar, Klaus: 45 articles (02/2008 - 02/2002)
8.	Richardson, Paul: 38 articles (07/2008 - 02/2002)
9.	Harousseau, Jean-Luc: 31 articles (09/2008 - 02/2002)
10.	Rajkumar, S Vincent: 31 articles (09/2008 - 12/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Multiple Myeloma:

1.	Thalidomide (Thalomid)FDA Link 06/01/2004 - "OBJECTIVES: Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities. " 01/01/2004 - "s-Thalidomide has proven efficacy in multiple myeloma. " 01/01/2003 - "Thalidomide is presently used in therapy of patients with resistant and relapsed multiple myeloma with very promising results." 01/01/2002 - "INTRODUCTION: Thalidomide has recently proven to be a useful drug for treatment of refractory and relapsed multiple myeloma patients, up to 35% of whom achieve remission. " 07/01/2008 - "Low efficacy of thalidomide in improving response after induction in multiple myeloma patients who are candidates for high-dose therapy." Order ALL the reference details at left...
2.	bortezomib (Velcade)FDA Link 10/01/2007 - "In the Japanese phase I/II study of bortezomib for relapsed multiple myeloma, this agent showed remarkable efficacy, with acceptable toxicities and unique pharmacokinetic/pharmacodynamic profiles, warranting further investigations, including more relevant administration schedules." 01/01/2009 - "We here reported a case of rare MCD complicated with multiple myeloma who received bortezomib and achieved very good remission. " 08/01/2007 - "Multiple myeloma patients treated with bortezomib have gained a high overall response rate and complete remission rate. " 05/01/2006 - "Bortezomib has shown significant activity in trials of patients with relapsed or refractory multiple myeloma; approximately one third of patients have shown significant improvement with bortezomib monotherapy in phase II and III clinical trials. " 02/01/2008 - "CONCLUSION: Bortezomib-based combinations therapy is an effective and safe induction regimen for newly diagnosed multiple myeloma patients and appears significantly superior to VAD, yielding high response rates even in patients with poor prognostic features." Order ALL the reference details at left...
3.	Dexamethasone (Maxidex)FDA LinkGeneric 01/01/1998 - "The authors describe a case of multiple myeloma in which a complete remission was obtained by treatment with high dose dexamethasone. " 02/01/1999 - "The use of biological modifiers in combination with dexamethasone offer a safe and effective therapeutic option in patients with refractory multiple myeloma. " 07/01/2009 - "Our aim in the present study was to use genomic screening to identify genes targeted for epigenetic inactivation in multiple myeloma and assess their role in the development of resistance to dexamethasone. " 02/15/2006 - "This study supports the strategy of combining dexamethasone with mTOR inhibitors in multiple myeloma and identifies a mechanism by which the synergistic effect is achieved." 01/01/2006 - "The present study investigates whether PCDGF/GP88 expression in multiple myeloma cells leads to the development of resistance to dexamethasone, a conventional drug for multiple myeloma patients. " Order ALL the reference details at left...
4.	Melphalan (Alkeran)FDA Link 01/01/1992 - "These results indicate that although VBAD is effective in at least one third of patients with advanced multiple myeloma resistant to melphalan, its impact on survival is limited." 03/01/1989 - "The response rate and the low toxicity observed in this group of patients are encouraging and suggest that intermediate-dose intravenous melphalan is an effective and safe second line treatment for patients with multiple myeloma not responding to conventional treatment." 04/01/1996 - "Melphalan has brought the first improvement in the therapy of multiple myeloma at the beginning of the sixties. " 01/01/1996 - "Melphalan has brought the first improvement in the therapy of multiple myeloma at the beginning of the sixties. " 07/01/2007 - "Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial." Order ALL the reference details at left...
5.	Proteasome Endopeptidase Complex (Proteasome)IBA 08/19/2003 - "Novel agents that target the proteasome, a proteolytic complex responsible for the degradation of ubiquitinated proteins, have demonstrated remarkable therapeutic efficacy in multiple myeloma, a plasma cell malignancy. " 03/26/2009 - "Proteasome inhibitors (PIs) are effective against multiple myeloma (MM), but the mechanisms of action and bases of individual susceptibility remain unclear. " 01/01/2008 - "Proteasome inhibition is now established as an effective treatment for relapsed and refractory multiple myeloma and offers great promise for the treatment of other haematological malignancies, when used in combination with conventional therapeutic agents. " 10/01/2003 - "First generation proteasome inhibitors are currently showing promise in phase II/III clinical trials for patients with multiple myeloma." 12/01/2001 - "Proteasome inhibitor holds promise for patients with refractory multiple myeloma." Order ALL the reference details at left...
6.	lenalidomide (CC 5013)FDA Link 07/23/2009 - "Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma." 04/01/2008 - "METHODS: A pooled analysis was performed of patients with previously untreated multiple myeloma enrolled in clinical trials of lenalidomide-based therapy at the Mayo Clinic, Rochester, Minnesota, and the Italian Myeloma Network, Italy. " 11/15/2006 - "A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma." 02/01/2006 - "Lenalidomide (CC-5013) is currently in Phase III trials for the treatment of multiple myeloma and MDS. " 11/01/2009 - "Lenalidomide in multiple myeloma." Order ALL the reference details at left...
7.	Prednisone (Sone)FDA LinkGeneric 05/01/1976 - "(1,3 di[2-chloroethyl]-1-nitrosourea) (30 mg/m2 of each intravenously every 3-4 weeks) was used to treat thirteen multiple-myeloma patients who did not respond or were in relapse after remission produced by alkylating-agent/prednisone therapy. " 01/01/1994 - "PURPOSE: The purposes of this study were (1) to estimate the response rate of alternate-day high dose prednisone in patients with relapsing and refractory multiple myeloma; (2) to measure the rate of GR levels; and (3) to correlate the response of prednisone with GR status. " 01/01/1975 - "A study was designed to evaluate the effectiveness of prednisone therapy in poor-risk patients with multiple myeloma. " 05/01/2002 - "Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients." 01/01/1994 - "CONCLUSIONS: Alternate-day high-dose prednisone was well tolerated and may provide palliative benefit for a subset of patients with relapsing and refractory multiple myeloma. " Order ALL the reference details at left...
8.	Cyclophosphamide (Cytoxan)FDA LinkGeneric 04/01/2001 - "High-dose cyclophosphamide (HDC) has been shown to be an effective regimen for collecting PBPC in multiple myeloma (MM) patients, but the optimal dose to be used remains controversial. " 08/01/1995 - "The aim of the study was to evaluate the feasibility and the efficacy of high-dose chemoradiotherapy followed by autologous hematopoietic stem cell support with peripheral blood progenitor cells (PBPC) harvested after high-dose cyclophosphamide (HDCYC) treatment in patients with high-risk multiple myeloma (MM). " 06/01/2007 - "To date, no systematic clinical study has investigated high-dose cyclophosphamide mobilization regimens in multiple myeloma patients and evaluated its cardiotoxicity. " 09/15/1999 - "The current study was designed to evaluate the effect of adding alternating cycles of IFN or early intensification with high dose cyclophosphamide (HiCy) to the VBMCP regimen for the treatment of multiple myeloma patients. " 05/01/1994 - "Therefore, this study indicates that the preferred form of high dose cyclophosphamide for multiple myeloma is as a single agent given in intravenous four day courses." Order ALL the reference details at left...
9.	Vincristine (Oncovin)FDA LinkGeneric 11/01/1985 - "A phase 2 trial of vincristine infusion was conducted in a group of 21 patients with refractory multiple myeloma. " 06/30/1980 - "Effect of vincristine on the bone marrow cells of patients with multiple myeloma: a cytomorphologic study." 11/01/1985 - "Vincristine infusion appears to have limited activity in the treatment of refractory multiple myeloma. " 11/01/1985 - "Single agent vincristine by infusion in refractory multiple myeloma." 01/01/1981 - "Effect of vincristine on bone marrow cells of patients with multiple myeloma. " Order ALL the reference details at left...
10.	Doxorubicin (Adriamycin)FDA LinkGeneric 12/01/2001 - "This study examined whether an Adriamycin-resistant multiple myeloma (MM) cell line (8226/Dox40) can be sensitized by Adriamycin (ADR) to Apo2L/TRAIL-mediated apoptosis. " 07/01/2003 - "CONCLUSIONS: Our multicenter trial, which included an unselected patient population, indicated that both VAD bolus and VAD doxil can be administered to outpatients and can provide an equal opportunity of rapid response in many patients with multiple myeloma." 06/01/2000 - "Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo." 08/18/1997 - "Decreased CP-1 (NF-Y) activity results in transcriptional down-regulation of topoisomerase IIalpha in a doxorubicin-resistant variant of human multiple myeloma RPMI 8226." 09/01/1983 - "These results supported the utility of a more frequent corticosteroid schedule with increased doxorubicin dose in patients with advanced and resistant multiple myeloma." Order ALL the reference details at left...

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 12/01/2005 - "BACKGROUND AND OBJECTIVES: Clinical trials have shown that high dose chemotherapy (HDT) with peripheral stem cell autotransplantation is presently the best treatment for patients with symptomatic multiple myeloma (MM). " 04/01/2006 - "Multiple myeloma is the second most common haematological malignant disease, but cannot be cured with conventional and high-dose chemotherapy. " 12/15/1996 - "BACKGROUND: A number of studies have demonstrated that high dose chemotherapy, with or without radiotherapy, with autologous marrow and/or peripheral blood progenitor cell support can result in improved overall and complete response rates in patients with multiple myeloma, and a minority of patients become long term survivors. " 12/01/2008 - "Multiple myeloma is an incurable clonal B-cell malignancy, which is initially responsive to conventional chemotherapy; one-third of the patients achieve complete remission but multidrug resistance eventually develops. " 07/01/2001 - "The introduction of high-dose treatment (HDT) with autologous hematopoietic stem cell support in patients with multiple myeloma (MM), although curative in only a minority of patients, has led to significantly longer event-free (EFS) and overall survival (OS) and likely improved quality of life compared with conventional chemotherapy. " Order ALL the reference details at left...
2.	Stem Cell Transplantation 11/15/2008 - "Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation." 12/01/2007 - "Whether these early results will lead to prolonged overall survival and thereby ultimately redefine the role of stem cell transplantation in first-line treatment of multiple myeloma will be one of the most important questions to be answered in the coming years. " 04/01/2008 - "OBJECTIVE: To evaluate the efficacy of autologous stem cell transplantation (ASCT) in the treatment of multiple myeloma (MM) and its impact on the prognosis of MM. METHODS: Retrospective analysis was performed in 28 patients with MM (group A) treated with ASCT in our hospital from October 1998 to February 2007, compared with those not received ASCT in the same time period including 23 patients with near complete response (nCR) or better (group B) and 25 patients with partial response (PR) (group C). " 11/01/2006 - "Induction regimens prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma patients usually result in complete remission (CR) rates of <10%. " 01/01/2004 - "High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission." Order ALL the reference details at left...
3.	Transplants (Transplant) 02/01/2005 - "High-dose treatment (HDT) with autologous stem cell transplant(s) (ASCT) improved survival, when compared to standard treatment, in multiple myeloma patients. " 06/01/2004 - "The application of high-dose treatment with autologous stem cell transplant(s) has improved survival, when compared to standard treatment, in patients with multiple myeloma. " 08/01/1994 - "High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants." 03/15/1999 - "To more definitively assess the safety and efficacy of CD34 selection, a phase III study was completed in 131 multiple myeloma patients randomized to receive an autologous transplant with either CD34-selected or unselected peripheral blood progenitor cells after myeloablative therapy. " 01/01/2000 - "The relapse of multiple myeloma following allogeneic transplant is a major problem and consequently the preparative regimens must be improved. " Order ALL the reference details at left...
4.	Combination Drug Therapy (Combination Chemotherapy) 09/01/1995 - "Our case indicated that one must include in the differential diagnosis of an osteosclerotic lesion the possibility of multiple myeloma, and that combination chemotherapy can induce a complete remission in this disease." 06/01/2008 - "Combination chemotherapy regimens have been developed providing high remission rates and remission quality in frontline treatment or in the relapsed setting in multiple myeloma. " 08/01/1993 - "Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. " 08/01/1986 - "Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study." 01/01/1998 - "[The efficacy of polychemotherapy programs in treating multiple myeloma patients]" Order ALL the reference details at left...
5.	Transplantation (Transplant Recipients) 10/01/2003 - "Autologous peripheral blood stem cell (PBSC) transplantation proved to increase complete remission (CR) and DFS in multiple myeloma (MM) patients. " 02/01/2005 - "Together with the rather good results in survival, the evaluation of quality of life invites further exploration of double transplantations in multiple myeloma." 06/01/2005 - "Therefore, the reduced allogeneic treatment approach in patients with multiple myeloma has still to be improved and further preclinical and clinical research is focused on two major issues: (i) to further reduce treatment-related mortality and (ii) to enhance the remission status after transplantation, via adoptive immunotherapy inducing molecular remission and enhancing the cure rate of this approach." 02/01/1998 - "We describe a patient with multiple myeloma who was treated with intensive therapy and autologous blood cell transplantation as her first-line treatment. " 05/01/2004 - "Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Multiple Myeloma

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 651 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>